GenEditBio

GenEditBio

Private
Hong KongHealthcare & Life Scienceshttps://geneditbio.com/

Last Round

Strategic

Sep 30, 2024

Total Funding Raised

$10.54M

Company Overview

GenEditBio is a biotechnology company that develops in vivo genome editing-based therapeutic solutions for genetic diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting, Government Contracts

AI Layer

Application

Keywords

gene editingCRISPRin vivo gene editinggene therapydrug delivery systemgenetic disease therapylipid nanoparticleLNPCas nucleaserare disease treatmentprotein delivery vehiclePDVclinical stage biotechcurative treatmentAI drug discovery

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

GenEditBio Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

GenEditBio Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
StrategicSep 30, 2024
Early FundingApr 4, 2024
GrantMar 1, 2024
Early FundingMay 25, 2022

Key People

Founding team and executive leadership

Tian Zhu

CEO & Co-Founder

Founding Team

GenEditBio Investors

Notable investors and investment history

InvestorRounds
FountainVest PartnersEarly Funding
HKSTP VenturesEarly Funding
Qiming Venture PartnersGrant, Early Funding
Innovation and Technology Venture FundGrant, Early Funding
Gobi Partners GBAStrategic

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 16, 2025

    Grew 17% QoQ from 18 to 21 employees.

  • Sep 30, 2024

    Led by Gobi Partners GBA.

GenEditBio Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

GenEditBio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about GenEditBio's valuation, stock price, and market status.

Firmographic Details

HeadquartersHong Kong
Employee Range22
Year Founded2021
Last FundingSep 30, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.